Latest Cambodian News
BEIJING and DALLAS, July 29, 2014 /PRNewswire/ — NQ Mobile (NYSE: NQ), a leading global provider of mobile Internet services, today announced it has been selected as the partner security services provider for Brightstar 20:20 Mobile. Under the license…
TORONTO, July 29, 2014 /PRNewswire/ — The next generation of Vexilor V10 tablets have launched with an integrated magnetic stripe reader (MSR) and unique Plug and Play capabilities.
Photo – http://photos.prnewswire.com/prnh/20140718/128655
Researched and designed with the help of business partners, Vexilor is an agile POS that is more than an iPad App. Vexilor is an enterprise level POS solution using tablets that are not only designed to look sleek and enhance any business environment, but are also custom manufactured strong enough to withstand rough handling and a range of indoor and outdoor business settings.
Enterprise level businesses used to be held back by the expenses associated with purchasing, installing, and maintaining legacy POS systems. For less than the costs businesses were traditionally spending on three or four legacy POS stations, Vexilor V10 tablets can create five or six of the same. Businesses have been able to speed up cash-out times, decrease table-turn times, and increase operational efficiencies across multiple industries.
The V10 Gen 2 Vexilor tablets build upon the well-received V10 Gen 1 tablets and are designed to meet the growing demands of enterprise businesses. A built-in magnetic stripe card reader (not just a dongle) for processing transactions involving Givex gift or loyalty cards and coupon redemptions is one of the enhanced business features of the Vexilor V10 Gen 2 tablets.
The V10 Gen 2 tablets can easily be mounted to serve as workstations or customer facings screens. Powered over Ethernet (POE), they don’t rely on secondary power cords or bulky wall warts, it’s as simple as plugging in one cable and businesses are ready to go. More stable than WiFi, Ethernet gives operators peace of mind when running their businesses, no more worrying about splitters, chargers, or unstable internet connections.
“The enhancements to the Vexilor V10 Gen 2 tablets are a result of Givex working closely with our clients to deeply understand their business needs and demands of their respective industries, and working to always evolve with those needs and demands” says Graham Campbell, SVP Product Development at Givex. He furthers “the Gen 2 Vexilor V10 tablets speak to Vexilor’s agile development, and our commitment to help businesses unleash their full potential.”
Vexilor is being used by businesses in USA, Canada, UK, Australia, Hong Kong, and mainland China.
BEIJING, July 29, 2014 /PRNewswire/ — China Biologic Products, Inc. (NASDAQ: CBPO, “China Biologic” or the “Company”), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release second…
LONDON, July 29, 2014 /PRNewswire/ — The healthcare industry is rapidly moving from a provider-centric, individual physician expertise-based service sector to a patient-centric, consultative and analytics-driven industry. This collaborative approach will be quickened by innovations that lend momentum to the integration of healthcare systems. Integrated care services can be achieved along four lines: patient engagement, workflow management, new healthcare models, and home care.
New analysis from Frost & Sullivan, Innovations in Home Medical Devices and Integrated Care Systems, finds that the integration of healthcare systems has several connotations. Integration can either be vertical, which results in consolidation of similar services, or horizontal, which aims at expansion of organization infrastructure and patient base. Integration can also be more microscopic, involving functions, organisational policies and clinical locations.
“The holy grail of integrated care systems is achieving end-to-end integration, which would require both vertical and horizontal consolidation that results in the streamlining of treatment services, products, ancillary and support systems as well as geographical expansion,” said Technical Insights Research Analyst Bhargav Rajan.
The biggest challenge to integration, especially in emerging economies, is the highly fragmented healthcare market. Enforcing common management policies and patient services among different practices to achieve functional clinical integration will be an uphill task.
In such regions, integration can be achieved by targeting readily available avenues for growth, such as implementing technological resources to ensure care of patients at home and in the community. In turn, remote patient monitoring and telemedicine will not only serve as tools for clinical services and patient integration, but also as a means of frugal innovation.
Healthcare providers and administrators need to realise that the consolidation of practices will not necessarily lead to integration of services. Effective integration requires alignment of practices and policies as well as culture and ideologies.
“For every successful case of healthcare integration, there are several instances of failed mergers, most notably among healthcare organisations with divergent mission statements,” cautioned Rajan. “Meeting of organisation goals and resource compatibility are important criteria during mergers and horizontal expansion.”
If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com
Innovations in Home Medical Devices and Integrated Care Systems, a part of the Technical Insights subscription, highlights key innovations in healthcare delivery, with special focus on identifying different strategies that providers can adopt to implement integration of services. This research service also provides a holistic analysis of various component technologies in accordance with their technical capabilities, market needs and industry requirements. Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact
Anna Zanchi
Corporate Communications — Europe
P: +39-02-4851-6133
E: anna.zanchi@frost.com
ROLLING MEADOWS, Ill., July 29, 2014 /PRNewswire/ — Cambium Networks™, a global leading provider of wireless broadband solutions, today announced the release of the ePMP Force 100, a high-gain integrated subscriber solution. The ePMP Force 100 contains Cambium Networks’ latest ePMP software release 2.1 that includes enhancements to Cambium Networks’ eFortify™ and eCommand™ software solutions.
Logo – http://photos.prnewswire.com/prnh/20140613/117974
The ePMP Force 100 can be deployed as a subscriber module that can connect to any ePMP access point, as well as peer nodes in point-to-point deployment configurations. Service providers who already have the ePMP 1000 Connectorized Radio in their networks have the option of purchasing the ePMP Dish separately to enhance throughput and increase deployment range. Key features of the ePMP Force 100:
Also announced today is software release 2.1 which adds software enhancements to eCommand which provides a suite of management tools to plan, provision and monitor the network, and to eFortify, which allows the platform to recognize and react to external interference.
eCommand improvements include:
eFortify improvements include:
“Helping our customers maximize their investments in equipment and realize faster ROI is a top priority for Cambium Networks,” said Atul Bhatnagar, president and CEO, Cambium Networks. “The ePMP Force 100 is a solid option for potential customers deploying across a range of physical and RF environments and subscriber densities, and allows networks operators to reach more end users while enhancing link performance.”
The ePMP Force 100 is the latest addition to the ePMP platform launched in October 2013, which includes:
To find out more about Cambium Networks™ go to www.cambiumnetworks.com, or follow @CambiumNetworks on Twitter and like us on Facebook for industry updates.
Additional information:
Download the product spec sheet: ePMP Force 100
Download release 2.1: ePMP Software
Read the blog post: Our Ally is the Force
Contact
Golin for Cambium Networks – Sara Ball
+1-415-318-4361
sball@golinharris.com
TAIPEI, July 29, 2014 /PRNewswire/ — 4ipnet, a leading provider of competitive and comprehensive wireless LAN solutions for meeting the Wi-Fi demands of tomorrow, today announced the launch of its newest indoor 802.11ac access points, the EAP760 and t…
SHANGHAI, July 29, 2014 /PRNewswire/ — Noah Holdings Limited (NYSE: NOAH; the “Company” ), a leading wealth management service provider focusing on distributing wealth management products to the high net worth population in China, today announced that…
BEIJING, July 29, 2014 /PRNewswire/ — Exceed Company Ltd. (EDS) (“Exceed” or the “Company”), one of the leading domestic sportswear brands in China, today announced that it has further adjourned its extraordinary general meeting of shareholder…
 |
MOUNTAIN VIEW, California, July 29, 2014 /PRNewswire/ — Drug development for hepatitis C virus (HCV) antivirals has amplified with rising incidence rates and the intense need for curative therapy in the absence of a preventative vaccine. Change is underway as the market moves away from protease inhibitors and interferon regimens towards highly effective, easily-tolerated, interferon-free oral therapies.
Gilead’s mega blockbuster Sovaldi is the first of these novel therapies to launch into the market and is projected to hit close to $10 billion during its first year. Several strong competitors, however, are maneuvering aggressively to narrow the market gap by introducing a HCV antiviral that can outdo Gilead’s drug.
New analysis from Frost & Sullivan’s A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market expects robust demand for HCV antivirals as around 160 million people across the globe are chronically infected with HCV, and at least 350,000 die annually from HC-infected liver diseases such as liver cancer and conditions requiring transplantation. The United States alone accounts for nearly five million of the total HCV-affected population, with the majority being baby boomers entering the 65-plus age bracket.
For complimentary access to more information on this research, please visit: http://bit.ly/1lOeo6Q
“Evidently, chronic infection with HCV remains a serious public health threat,” said Frost & Sullivan Healthcare Principal Analyst Randy Budros. “Until an efficacious preventative vaccine emerges, the patient strength will remain sizable due to the likelihood of high-risk behaviors from a substantial portion of the population and the emergence of resistant viral strains.”
While Gilead’s Sovaldi holds promise in fighting the HCV, its astronomical price – $84,000 for a 12-week course of treatment – has unleashed a firestorm of criticism from government agencies, patient advocacy groups, and payers. Indeed, the prohibitive price has triggered a Congressional request for Gilead to justify its pricing, which is projected to increase Medicare Part D spending by as much as $6.5 billion in 2015 alone.
“Gilead and other future market entrants have to create a compelling pricing rationale by driving home the potential cost savings from a high-performance, all-oral regime, zeroing in on the downstream cost saving such as the reduction of liver transplants,” noted Budros. “Equally crucial is the need to make HCV antivirals more affordable and accessible to patients.”
With recent clinical data showing close to 100-percent cure rates for Sovaldi, future contenders will be hard pressed to succeed in the marketplace. Competitors must aim to satisfy the until now unmet need for a once-daily, ribavirin-free, all-oral, pan-genotypic regimen that has a short treatment duration.
A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV) Antiviral Market is part of the Life Sciences (http://www.lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Product and Pipeline Analysis of the Global Therapeutic Lipid Modulators Market, A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market, A Strategic Analysis of the Global Anti-obesity Prescription Pharmaceuticals Market, and Product and Pipeline Analysis of the Global Psoriasis Therapeutics Market. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Connect with Frost & Sullivan on social media, including Twitter, Facebook, SlideShare and LinkedIn, for the latest news and updates.
— Smart fertilizers, PGRs, and bundled micronutrients are fast growing niche segments that will challenge bulk fertilizers in the market
MOUNTAIN VIEW, Calif., July 29, 2014 /PRNewswire/ — The plant health improvement agents (PHIA) market, which consists of micronutrients, synthetic fertilizers and plant growth regulators (PGRs), is growing steadily in North America mainly due to demand from the food, biofuel and plant-based chemicals industries. Rising healthcare costs combined with healthier eating trends have resulted in increased demand for high-value niche foods such as proteins, nuts, vitamins and minerals allowing for increased PHIA use in horticulture. The Renewable Fuel Standard and other regulations aimed at reducing carbon footprint through use of biofuels and natural products further support market demand.
New analysis from Frost & Sullivan, Analysis of the North American Plant Health Improvement Agents (PHIA) Market, finds that the market earned revenues of $15.45 billion in 2013 and estimates this to reach $19.66 billion by 2020. While synthetic fertilizers dominate the North American market with a 91.4 percent share, educated farmers are influencing the development and marketing of high-value products such as micronutrients and PGRs.
For complimentary access to more information on this research, please visit: http://bit.ly/1rwnrgr.
“Rapid advances in plant genetics and seed technology can outpace nutrient innovation and reduce dependence on standard bulk fertilizers,” said Frost & Sullivan Chemicals, Materials and Food Research Analyst Reuben Sequeira. “To sidestep this threat, PHIA market participants are developing new plant nutrient technologies, such as chelated and complexed micronutrients to complement the modern plant.”
However, fluctuating weather, planting and demand patterns in the region alter the balance of nutrient supply and demand creating price volatility in the PHIA market. While nutrient companies are adapting, this issue still affects upstream capacity utilization, especially as excess supply lowers nutrient prices for prolonged periods of time.
Companies that have sustained above-market growth in the midst of demand and price instability are those that maintain strong relationships with customers through well-developed distribution pipelines. These companies anticipate concerns and reduce risk through long-term contracts that ensure steady return on investment for growers.
“Such distribution partnerships will help suppliers meet growers’ needs with highly effective and advanced products,” noted Sequeira. “Innovative products, such as controlled-release fertilizers, micronutrient-bulk fertilizer blends, and targeted micronutrients will also morph into substitutes for bulk nutrients.”
Analysis of the North American Plant Health Improvement Agents (PHIA) Market is part of the Chemicals & Materials (http://www.chemicals.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Analysis of the Western European Plant Health Improvement Agents Market, among others. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.